AG1 (Athletic Greens): Clinical Gaps and Limitations You Should Know

No Published RCT Has Tested the Finished Product

AG1 has never been the subject of a published, peer-reviewed randomized controlled trial. This is the single most important gap in its evidence base, and it separates AG1 from pharmaceutical products that must demonstrate efficacy before reaching consumers.

The FDA regulates dietary supplements under the 1994 Dietary Supplement Health and Education Act (DSHEA), which does not require pre-market proof of efficacy [1]. Manufacturers can make structure/function claims without clinical trial data, provided they include the standard disclaimer. AG1's marketing language ("foundational nutrition") stays within this framework but implies a breadth of benefit that no trial on the product has confirmed.

This matters because multi-ingredient formulas can behave differently than their individual components. Nutrient-nutrient interactions (calcium inhibiting iron absorption, zinc competing with copper uptake) may reduce or alter the bioavailability of specific compounds when combined [2]. The Physicians' Health Study II (N=14,641) tested a specific multivitamin (Centrum Silver) over 11.2 years and found a modest 8% reduction in total cancer incidence (HR 0.92 to 95% CI 0.86, 0.998) but no effect on cardiovascular events [3]. That result applies to Centrum Silver's specific formulation. It cannot be transferred to AG1.

Without product-specific trial data, claims about AG1's effects remain extrapolations from studies on individual ingredients tested at known doses in different populations.

Proprietary Blends Obscure What You Actually Get

AG1 lists four proprietary blends on its label: a "Raw Alkaline Superfood Complex," a "Nutrient Dense Extracts, Herbs & Antioxidants" blend, a "Digestive Enzyme & Mushroom Complex," and a "Dairy-Free Probiotics" blend. For each blend, only the total weight is disclosed. Individual ingredient quantities within each blend are not listed.

This is legal. FDA labeling regulations require listing ingredients in descending order of predominance within a proprietary blend, but individual weights are optional [1]. The practical consequence: consumers cannot verify whether any single botanical or adaptogen is present at a clinically meaningful dose.

Take ashwagandha as an example. The randomized trial by Chandrasekhar et al. (N=64) that demonstrated cortisol reduction used 300 mg of a standardized root extract (KSM-66) twice daily, totaling 600 mg/day [4]. AG1 lists ashwagandha within a proprietary blend, but the total blend weight must be divided among roughly 15 other ingredients. Whether the ashwagandha dose reaches even 300 mg is unknown from the label alone. The same uncertainty applies to Rhodiola rosea, milk thistle, and every other botanical in the formula.

Some vitamins and minerals are listed with specific amounts outside the proprietary blends (vitamin C at 420 mg, vitamin E at 89.4 mg, and so on). But the bioactives that differentiate AG1 from a standard multivitamin are precisely the ones hidden inside proprietary blends.

Vitamin and Mineral Doses: Some Too High, Others Too Low

Where AG1 does disclose specific micronutrient amounts, the doses reveal a pattern of overdelivery for water-soluble vitamins and potential underdelivery for nutrients where dose-response data suggests higher targets.

Vitamin C is listed at 420 mg per serving (467% of the Daily Value). The body saturates ascorbic acid absorption at roughly 200 mg per dose; amounts above this threshold are largely excreted renally [5]. A 420 mg dose is not harmful, but the excess confers no demonstrated additional benefit for most adults.

B-vitamin doses follow a similar pattern. Vitamin B12 appears at 7.2 mcg (300% DV), and biotin at 150 mcg (500% DV). For individuals without confirmed deficiency, supraphysiologic B-vitamin intake has not shown benefit in large trials. The USPSTF's 2022 recommendation found insufficient evidence that supplementation with most individual vitamins or minerals prevents cardiovascular disease or cancer in the general adult population [6].

Vitamin D, on the other hand, sits at 25 mcg (1 to 000 IU). While this exceeds the RDA of 15 to 20 mcg for most adults, deficiency correction protocols routinely use 50 to 125 mcg (2,000, 5 to 000 IU) daily [7]. For the estimated 42% of U.S. adults with vitamin D levels below 20 ng/mL, AG1's dose may not move the needle fast enough [8]. A person relying solely on AG1 for vitamin D repletion could remain insufficient for months.

Magnesium appears as magnesium citrate, but the dose is buried in a proprietary blend. Given that the Recommended Dietary Allowance ranges from 310 to 420 mg depending on age and sex, and that most Americans consume below the RDA, an undisclosed magnesium dose is a notable gap [2].

The Single-Strain Probiotic Limitation

AG1 contains 7.2 billion CFU of Lactobacillus acidophilus UALa-01. This is a single-strain probiotic at a moderate colony count.

The probiotic evidence base is strain-specific. A Cochrane review on probiotics for preventing Clostridium difficile-associated diarrhea (23 RCTs, N=4,213) found benefit with multi-strain preparations at doses of 10 billion CFU or higher [9]. The specific strain L. acidophilus UALa-01 has limited independent clinical trial data compared to well-studied strains like Lactobacillus rhamnosus GG or Saccharomyces boulardii.

For general gut health, the American Gastroenterological Association's 2020 guidelines recommend against probiotic use for most GI conditions outside of specific clinical scenarios (pouchitis prevention, C. difficile prevention in antibiotic-treated adults) [10]. A single-strain probiotic at 7.2 billion CFU does not align with the multi-strain, higher-dose protocols that showed efficacy in positive trials.

The claim that AG1 supports "gut health" rests on this single strain plus a digestive enzyme blend of undisclosed potency. Without clinical testing of the finished formula, the actual effect on microbiome composition or digestive symptoms is speculative.

Adaptogen and Superfood Claims Lack Product-Level Evidence

AG1's formula includes spirulina, chlorella, wheat grass, barley grass, Rhodiola rosea, astragalus, and reishi mushroom, among others. Each of these ingredients has some preliminary research, but the evidence is fragmented and often derived from doses higher than what AG1 likely provides.

Rhodiola rosea trials showing fatigue reduction used 200 to 600 mg of standardized extract (3% rosavins, 1% salidroside) daily [11]. AG1's Rhodiola dose is unknown. Reishi mushroom studies on immune modulation used 1.5 to 5.4 g of extract daily [12]. AG1 lists reishi within a blend that totals far less than 5.4 g across all its constituents.

Spirulina has the most consistent data among the "superfood" ingredients, with a meta-analysis of 12 RCTs showing modest reductions in total cholesterol (weighted mean difference: -35.4 mg/dL) and LDL (weighted mean difference: -24.3 mg/dL) at doses of 1 to 10 g daily [13]. Whether AG1 delivers even 1 g of spirulina per scoop is not determinable from the label.

The word "superfood" has no regulatory definition. The European Food Safety Authority (EFSA) and the FDA do not recognize it as a category. When AG1 positions itself as a "foundational" supplement containing superfoods, the terminology is marketing language, not a scientific classification.

Cost vs. Targeted, Dose-Transparent Alternatives

AG1 retails at approximately $79 per month on subscription (30 servings). This positions it as a premium product. The relevant question: does the cost match the evidence?

A comparable approach using individual supplements with disclosed, clinically tested doses might include: a standard multivitamin ($8, 15/month), vitamin D3 at 2,000, 5 to 000 IU ($5, 8/month), magnesium glycinate at 200 to 400 mg ($8, 12/month), and a multi-strain probiotic at 10+ billion CFU ($15, 25/month). Total cost: $36, 60/month. Every ingredient dose is printed on the label.

The COSMOS trial tested Centrum Silver (retail ~$15 for 200 tablets) and found the modest cancer risk reduction noted above [3]. No greens powder at any price point has replicated that finding. Cost does not predict efficacy.

AG1 does hold NSF Certified for Sport certification, which verifies that the product is free from substances banned by major athletic organizations and that label claims match contents [14]. This third-party testing provides assurance against contamination and adulteration. It does not verify clinical efficacy.

For consumers who value convenience (one scoop versus four separate pills), AG1 offers a simplification benefit. That preference is legitimate. But convenience and clinical evidence are separate considerations, and the premium reflects the former more than the latter.

Who Might Benefit and Who Should Look Elsewhere

AG1 may serve as a nutritional backstop for healthy adults who eat a varied diet and want a convenient multivitamin-plus-greens product. The vitamins and minerals with disclosed doses fall within safe upper limits for healthy adults, and NSF certification reduces contamination risk.

AG1 is a poor fit for several groups. Individuals with diagnosed deficiencies (vitamin D <20 ng/mL, iron deficiency anemia, B12 deficiency) need targeted repletion at therapeutic doses that AG1 cannot reliably provide. Pregnant or breastfeeding individuals require specific prenatal formulations with 400 to 800 mcg folic acid, 27 mg iron, and 200 to 300 mg DHA, none of which AG1 is designed to deliver [15]. People taking prescription medications should review the formula with their prescriber, as ingredients like green tea extract, astragalus, and digestive enzymes can affect drug metabolism and absorption.

The Endocrine Society's 2024 guidelines on vitamin D supplementation recommend against population-wide screening but advise supplementation at 1,500, 2 to 000 IU daily for adults at risk of deficiency [7]. AG1's 1 to 000 IU sits below even this conservative target.

Anyone spending $79/month on a supplement should be able to answer two questions: what dose of each active ingredient am I receiving, and what trial tested this dose for my goal? AG1's proprietary blends make the first question unanswerable for most of its ingredients. The absence of product-specific trials makes the second question unanswerable for all of them.